about
Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials.Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma (ccRCC)A serum metabolomic fingerprint of bevacizumab and temsirolimus combination as first-line treatment of metastatic renal cell carcinoma
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Sunitinib for advanced renal cell cancer.
@en
Sunitinib for advanced renal cell cancer.
@nl
type
label
Sunitinib for advanced renal cell cancer.
@en
Sunitinib for advanced renal cell cancer.
@nl
prefLabel
Sunitinib for advanced renal cell cancer.
@en
Sunitinib for advanced renal cell cancer.
@nl
P2860
P356
P1476
Sunitinib for advanced renal cell cancer.
@en
P2093
Chris Coppin
P2860
P304
P356
10.2147/BTT.S1834
P577
2008-03-01T00:00:00Z